• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

植物天然产物对代谢相关脂肪性肝病的影响及其作用机制:以调节肠道菌群为重点的叙述性综述

Effects of plant natural products on metabolic-associated fatty liver disease and the underlying mechanisms: a narrative review with a focus on the modulation of the gut microbiota.

机构信息

School of Life Sciences and Medicine, Shandong University of Technology, Zibo, Shandong, China.

National Institute of Traditional Chinese Medicine Constitution and Preventive Medicine, Beijing University of Chinese Medicine, Beijing, China.

出版信息

Front Cell Infect Microbiol. 2024 Feb 20;14:1323261. doi: 10.3389/fcimb.2024.1323261. eCollection 2024.

DOI:10.3389/fcimb.2024.1323261
PMID:38444539
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10912229/
Abstract

Metabolic-associated fatty liver disease (MAFLD) is a chronic liver disease characterized by the excessive accumulation of fat in hepatocytes. However, due to the complex pathogenesis of MAFLD, there are no officially approved drugs for treatment. Therefore, there is an urgent need to find safe and effective anti-MAFLD drugs. Recently, the relationship between the gut microbiota and MAFLD has been widely recognized, and treating MAFLD by regulating the gut microbiota may be a new therapeutic strategy. Natural products, especially plant natural products, have attracted much attention in the treatment of MAFLD due to their multiple targets and pathways and few side effects. Moreover, the structure and function of the gut microbiota can be influenced by exposure to plant natural products. However, the effects of plant natural products on MAFLD through targeting of the gut microbiota and the underlying mechanisms are poorly understood. Based on the above information and to address the potential therapeutic role of plant natural products in MAFLD, we systematically summarize the effects and mechanisms of action of plant natural products in the prevention and treatment of MAFLD through targeting of the gut microbiota. This narrative review provides feasible ideas for further exploration of safer and more effective natural drugs for the prevention and treatment of MAFLD.

摘要

代谢相关脂肪性肝病(MAFLD)是一种以肝细胞脂肪过度堆积为特征的慢性肝病。然而,由于 MAFLD 的发病机制复杂,目前尚无官方批准的治疗药物。因此,迫切需要寻找安全有效的抗 MAFLD 药物。最近,肠道微生物群与 MAFLD 的关系已得到广泛认可,通过调节肠道微生物群来治疗 MAFLD 可能是一种新的治疗策略。天然产物,特别是植物天然产物,由于其多靶点和多途径以及副作用少,在治疗 MAFLD 方面引起了广泛关注。此外,植物天然产物的暴露可以影响肠道微生物群的结构和功能。然而,植物天然产物通过靶向肠道微生物群对 MAFLD 的影响及其潜在机制尚不清楚。基于上述信息,并为了探讨植物天然产物在 MAFLD 治疗中的潜在治疗作用,我们系统地综述了植物天然产物通过靶向肠道微生物群预防和治疗 MAFLD 的作用和作用机制。本综述为进一步探索更安全、更有效的天然药物预防和治疗 MAFLD 提供了可行的思路。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/372f/10912229/265239c8b704/fcimb-14-1323261-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/372f/10912229/9e49e47ba33f/fcimb-14-1323261-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/372f/10912229/6a4899f376f4/fcimb-14-1323261-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/372f/10912229/265239c8b704/fcimb-14-1323261-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/372f/10912229/9e49e47ba33f/fcimb-14-1323261-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/372f/10912229/6a4899f376f4/fcimb-14-1323261-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/372f/10912229/265239c8b704/fcimb-14-1323261-g003.jpg

相似文献

1
Effects of plant natural products on metabolic-associated fatty liver disease and the underlying mechanisms: a narrative review with a focus on the modulation of the gut microbiota.植物天然产物对代谢相关脂肪性肝病的影响及其作用机制:以调节肠道菌群为重点的叙述性综述
Front Cell Infect Microbiol. 2024 Feb 20;14:1323261. doi: 10.3389/fcimb.2024.1323261. eCollection 2024.
2
Regulation of Mitochondrial Function by Natural Products for the Treatment of Metabolic Associated Fatty Liver Disease.天然产物对线粒体功能的调控在代谢相关性脂肪性肝病治疗中的作用。
Can J Gastroenterol Hepatol. 2021 Jun 16;2021:5527315. doi: 10.1155/2021/5527315. eCollection 2021.
3
Non-alcoholic fatty liver disease in patients with morbid obesity: the gut microbiota axis as a potential pathophysiology mechanism.病态肥胖患者的非酒精性脂肪性肝病:肠道微生物群轴作为一种潜在的病理生理学机制。
J Gastroenterol. 2024 Apr;59(4):329-341. doi: 10.1007/s00535-023-02075-7. Epub 2024 Jan 24.
4
Mining Gut Microbiota From Bariatric Surgery for MAFLD.从减肥手术中挖掘 MAFLD 的肠道微生物群。
Front Endocrinol (Lausanne). 2021 Apr 9;12:612946. doi: 10.3389/fendo.2021.612946. eCollection 2021.
5
Role of gut microbiota and immune cells in metabolic-associated fatty liver disease: clinical impact.肠道微生物群和免疫细胞在代谢相关脂肪性肝病中的作用:临床影响。
Hepatol Int. 2024 Oct;18(Suppl 2):861-872. doi: 10.1007/s12072-024-10674-6. Epub 2024 Jul 12.
6
Influence of Gut Microbiota and its Metabolites on Progression of Metabolic Associated Fatty Liver Disease.肠道微生物群及其代谢物对代谢相关性脂肪性肝病进展的影响。
Chin Med Sci J. 2023 Dec;38(4):286-296. doi: 10.24920/004220.
7
Polysaccharides: The Potential Prebiotics for Metabolic Associated Fatty Liver Disease (MAFLD).多糖:代谢相关脂肪性肝病(MAFLD)的潜在益生元。
Nutrients. 2023 Aug 25;15(17):3722. doi: 10.3390/nu15173722.
8
Oroxin B improves metabolic-associated fatty liver disease by alleviating gut microbiota dysbiosis in a high-fat diet-induced rat model.脑肠肽素 B 通过改善高脂饮食诱导的大鼠模型中的肠道微生物群落失调来改善代谢相关脂肪性肝病。
Eur J Pharmacol. 2023 Jul 15;951:175788. doi: 10.1016/j.ejphar.2023.175788. Epub 2023 May 12.
9
Metabolic-Associated Fatty Liver Disease and the Gut Microbiota.代谢相关脂肪性肝病与肠道微生物群。
Endocrinol Metab Clin North Am. 2023 Sep;52(3):485-496. doi: 10.1016/j.ecl.2023.01.004. Epub 2023 Mar 1.
10
Mapping the human oral and gut fungal microbiota in patients with metabolic dysfunction-associated fatty liver disease.绘制代谢功能障碍相关脂肪性肝病患者的口腔和肠道真菌微生物群图谱。
Front Cell Infect Microbiol. 2023 Apr 26;13:1157368. doi: 10.3389/fcimb.2023.1157368. eCollection 2023.

引用本文的文献

1
Effect of dietary polyphenols along with exercise on hepatic transcriptional regulators of lipid metabolism.膳食多酚与运动对肝脏脂质代谢转录调节因子的影响。
Front Nutr. 2025 Jul 2;12:1531327. doi: 10.3389/fnut.2025.1531327. eCollection 2025.
2
Bacteroides uniformis-generated hexadecanedioic acid ameliorates metabolic-associated fatty liver disease.均匀拟杆菌产生的十六烷二酸可改善代谢相关脂肪性肝病。
Gut Microbes. 2025 Dec;17(1):2508433. doi: 10.1080/19490976.2025.2508433. Epub 2025 May 25.
3
Hepatic Steatosis Can Be Partly Generated by the Gut Microbiota-Mitochondria Axis via 2-Oleoyl Glycerol and Reversed by a Combination of Soy Protein, Chia Oil, Curcumin and Nopal.

本文引用的文献

1
Protective effects of blueberries on vascular function: A narrative review of preclinical and clinical evidence.蓝莓对血管功能的保护作用:临床前和临床证据的叙述性综述。
Nutr Res. 2023 Dec;120:20-57. doi: 10.1016/j.nutres.2023.09.007. Epub 2023 Sep 28.
2
Essential oil extracted from Quzhou Aurantii Fructus prevents acute liver failure through inhibiting lipopolysaccharide-mediated inflammatory response.从衢州枳壳中提取的挥发油通过抑制脂多糖介导的炎症反应预防急性肝衰竭。
Nat Prod Bioprospect. 2023 Oct 7;13(1):36. doi: 10.1007/s13659-023-00398-9.
3
Functional Properties of Natural Products and Human Health.
肝脂肪变性可以部分通过肠道微生物群-线粒体轴通过 2-油酰甘油产生,并通过大豆蛋白、奇亚籽油、姜黄素和龙舌兰的组合来逆转。
Nutrients. 2024 Aug 6;16(16):2594. doi: 10.3390/nu16162594.
4
NAFLD/MASLD and the Gut-Liver Axis: From Pathogenesis to Treatment Options.非酒精性脂肪性肝病/代谢功能障碍相关脂肪性肝病与肠-肝轴:从发病机制到治疗选择
Metabolites. 2024 Jun 28;14(7):366. doi: 10.3390/metabo14070366.
天然产物的功能特性与人类健康。
Nutrients. 2023 Jun 29;15(13):2961. doi: 10.3390/nu15132961.
4
Aqueous extract of Polygala japonica Houtt. ameliorated nonalcoholic steatohepatitis in mice through restoring the gut microbiota disorders and affecting the metabolites in feces and liver.远志水提物通过恢复肠道微生物群紊乱和影响粪便和肝脏代谢物来改善小鼠非酒精性脂肪性肝炎。
Phytomedicine. 2023 Sep;118:154937. doi: 10.1016/j.phymed.2023.154937. Epub 2023 Jun 20.
5
Ginsenosides Rc, as a novel SIRT6 activator, protects mice against high fat diet induced NAFLD.人参皂苷Rc作为一种新型的SIRT6激活剂,可保护小鼠免受高脂饮食诱导的非酒精性脂肪性肝病的影响。
J Ginseng Res. 2023 May;47(3):376-384. doi: 10.1016/j.jgr.2020.07.005. Epub 2020 Aug 4.
6
Nobiletin Ameliorates Nonalcoholic Fatty Liver Disease by Regulating Gut Microbiota and Myristoleic Acid Metabolism.川陈皮素通过调节肠道微生物群和豆蔻酸代谢改善非酒精性脂肪性肝病。
J Agric Food Chem. 2023 May 17;71(19):7312-7323. doi: 10.1021/acs.jafc.2c08637. Epub 2023 May 4.
7
The interplay between herbal medicines and gut microbiota in metabolic diseases.草药与肠道微生物群在代谢性疾病中的相互作用。
Front Pharmacol. 2023 Mar 24;14:1105405. doi: 10.3389/fphar.2023.1105405. eCollection 2023.
8
Vitamin D improves hepatic steatosis in NAFLD regulation of fatty acid uptake and β-oxidation.维生素 D 可改善非酒精性脂肪性肝病中的肝脂肪变性,调节脂肪酸摄取和β氧化。
Front Endocrinol (Lausanne). 2023 Mar 22;14:1138078. doi: 10.3389/fendo.2023.1138078. eCollection 2023.
9
α-D-1,3-glucan from Radix Puerariae thomsonii improves NAFLD by regulating the intestinal flora and metabolites.粉葛中的α-D-1,3-葡聚糖通过调节肠道菌群和代谢产物改善非酒精性脂肪性肝病。
Carbohydr Polym. 2023 Jan 1;299:120197. doi: 10.1016/j.carbpol.2022.120197. Epub 2022 Oct 8.
10
Vitamin D alleviates non-alcoholic fatty liver disease restoring gut microbiota and metabolism.维生素D通过恢复肠道微生物群和新陈代谢来缓解非酒精性脂肪性肝病。
Front Microbiol. 2023 Feb 2;14:1117644. doi: 10.3389/fmicb.2023.1117644. eCollection 2023.